SCHEMBL4430834

SCHEMBL4430834

Cc1ccc(C(=O)O)c(=O)n1Cc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.60
SMN1; SMN2 Q16637 4/20 0.54
ALDH1A1 P00352 4/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
KDM4E B2RXH2 2/20 0.54
GAA P10253 2/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
NR4A1 P22736 2/20 0.54
USP2 O75604 1/20 0.54
POLB P06746 1/20 0.54
MAPT P10636 1/20 0.54
THRB P10828 1/20 0.54
APEX1 P27695 1/20 0.54
APOBEC3A P31941 1/20 0.54
RECQL P46063 1/20 0.54
HIF1A Q16665 1/20 0.54
APOBEC3G Q9HC16 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
FABP4 P15090 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11611071 0.84 ERCC5 (0.48) NOTUMSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL11607355 0.83 PKM (0.51) NOTUMSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL19709656 0.80 ALDH1A1 (0.47) NOTUMSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL9597173 0.80 KLKB1 (0.48) NOTUMSMN1; SMN2CNR1CNR2MAPK1
SCHEMBL31560452 0.80 ALDH1A1 (0.57) NOTUMSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL4428277 0.79 NOTUM (0.48) NOTUMSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL2746512 0.78 NOTUM (0.61) NOTUMSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL7337363 0.78 HAAO (0.49) NOTUMSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL3054971 0.77 L3MBTL1 (0.62) NOTUMMEN1KMT2AL3MBTL1POLB
SCHEMBL9532751 0.77 AGTR1 (0.50) NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125739-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2009-12-02 EP disclosed
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof ENCYSIVE PHARMACEUTICALS, INC. 2008-08-07 US disclosed
WO-2008079371-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2008-07-03 WO disclosed
US-4104273-A Derivatives of 3-cyano-pyrid-2-ones ROHM AND HAAS COMPANY (US) 1978-08-01 US disclosed
US-4028084-A Derivatives of 3-carboxy pyrid-2-ones ROHM AND HAAS COMPANY (US) 1977-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof C3AR1, C5, C5AR1 NOTUM 3912/4885SMN1; SMN2 2273/4885ALDH1A1 1639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.